If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
It is an Agriculture society founded in 2008. Operational area of these society is Kerala and Tamil Nadu. Society's mission is socially, economically, and ecologically sustainable community development. Society help the farmers to get a reasonable return for their efforts in the soil by making them aware of various advanced techniques and methods of cultivation without harming the fundamental being of nature.
== Personnel == Fishbone Angelo Moore – saxophone, vocals Walter A. Kibby II – trumpet, vocals Kendall Jones – guitars, vocals Chris Dowd – keyboards, trombone, vocals John Norwood Fisher – bass, vocals Philip "Fish" Fisher – drums Additional personnel Lisa Grant – vocals on "Lyin' Ass Bitch" Production Nancy Donald – design David Kahne – engineer Tony Lane – design David Leonard – engineer, mixing John Scarpati – photography Jack Skinner – mastering (Sterling Sound, New York City)
continued beta cell death following diagnosis of type 1 diabetes (honeymoon period) growth spurts particularly during puberty weight gain or loss any drug treatment that affects insulin sensitivity (e.g. corticosteroids) eating, sleeping, or exercise routine changes whenever the control over hyperglycemia is degrading and according to the seasons. A pump user should be educated by their diabetes care professional about basal rate determination before beginning pump therapy.
Sources: en.wikipedia.org
== Mass spectrometry == Generally this topic is discussed when covering tandem mass spectrometry fragmentation and occurs generally by the same mechanisms. For example, of a mechanism of alpha-cleavage, an electron is knocked off an atom (usually by electron collision) to form a radical cation. Electron removal generally happens in the following order: 1) lone pair electrons, 2) pi bond electrons, 3) sigma bond electrons. One of the lone pair electrons moves down to form a pi bond with an electron from an adjacent (alpha) bond. The other electron from the bond moves to an adjacent atom (not one adjacent to the lone pair atom) creating a radical. This creates a double bond adjacent to the lone pair atom (oxygen is a good example) and breaks/cleaves the bond from which the two electrons were removed.
In Indonesia, the hardline anti-communist General Suharto wrested control from predecessor Sukarno in an attempt to establish a "New Order". From 1965 to 1966, with the aid of the US and other Western governments, the military led the mass killing of more than 500,000 members and sympathizers of the Indonesian Communist Party and other leftist organizations, and detained hundreds of thousands in prison camps under inhumane conditions. A top-secret CIA report stated that the massacres "rank as one of the worst mass murders of the 20th century, along with the Soviet purges of the 1930s, the Nazi mass murders during the Second World War, and the Maoist bloodbath of the early 1950s." These killings served US interests and constitute a major turning point in the Cold War as the balance of power shifted in Southeast Asia.
=== Fetus earrings === During the 1984 exhibition of freeze-dried sculptures in London, Gibson was given two dehydrated human fetuses from an anatomy professor. They were 10 weeks in development and had been dehydrated for 20 years. Gibson re-hydrated both fetuses, freeze-dried them and attached them as earrings to a female mannequin head. The sculpture was titled Human Earrings. They were exhibited at the Young Unknowns Gallery in south London in December 1987. On Thursday, 3 December 1987, the sculpture was seized by the Metropolitan Police. Because of this incident, Gibson was expelled from Goldsmiths College on 21 December 1987, where he was studying post-graduate art, design and technology. On 11 April 1988, Gibson and the gallery owner, Peter Sylveire, were formally charged with the common law offences of exhibiting a public nuisance and outraging public decency. The trial started on Monday, 30 January 1989 at the Old Bailey in central London. The judge was Brian Smedley, Michael Worsley was the prosecuting barrister, and Geoffrey Robertson and Helena Kennedy were the defence barristers. On 6 February 1989, the charge of public nuisance was dismissed. On Tuesday, 9 February 1989, the jury of 10 women and 2 men found Gibson and Sylveire guilty of outraging public decency. Gibson was fined £500 and Sylveire was fined £300. Immediately following the verdict, an appeal application was filed. However, on 10 July 1990, the Court of Appeal dismissed the case and upheld the earlier conviction.
Ayahuasca has a number of major contraindications due to its action as a monoamine oxidase inhibitor (MAOI) and the potential for serious drug interactions. These include concomitant use with serotonergic agents like selective serotonin reuptake inhibitors (SSRIs), MDMA, and dextromethorphan (DXM) due to risk of serotonin syndrome, sympathomimetics like amphetamines and cocaine due to risk of hypertensive crisis, and certain other drugs. Little information is available on ayahuasca in people with cardiovascular disease and whether there may be contraindications in this area. In any case, it has been said that cardiovascular problems, as well as endocrine problems, abnormal lipid metabolism, glaucoma, fever, and pregnancy are all contraindications of ayahuasca. Certain psychiatric disorders such as psychosis or bipolar mania or family history of such conditions may also be contraindications of ayahuasca.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.